Cetrelimab
- Product Name
- Cetrelimab
- CAS No.
- 2050478-92-5
- Chemical Name
- Cetrelimab
- Synonyms
- Cetrelimab;Cetrelimab (anti-PDCD1);Research Grade Cetrelimab;Research Grade Cetrelimab(DHH02204)
- CBNumber
- CB28081085
- Formula Weight
- 0
- MOL File
- Mol file
Cetrelimab Property
- form
- Liquid
- color
- Colorless to light yellow
Cetrelimab Chemical Properties,Usage,Production
Uses
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].
in vivo
Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8+ T cells in patient-derived xenograft (PDX) lung model in mice[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)[1].
| Animal Model: | hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; single dose at day 7 after tumor implantation |
| Result: | hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21. |
| Animal Model: | Patient-derived xenograft (PDX) LG1306 lung model in mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; every 5 days for 6 cycles |
| Result: | Significantly reduced patient-derived tumor volume by 32%. |
| Animal Model: | Good Laboratory Practice (GLP) toxicity study in cynomolgus[1] |
| Dosage: | 0, 10, 30, or 100 mg/kg |
| Administration: | Intravenous injection; once weekly for 5 weeks |
| Result: | Showed well tolerance in cynomolgus. |
References
[1] DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. DOI:10.1007/s00280-022-04415-5
Cetrelimab Preparation Products And Raw materials
Raw materials
Preparation Products
Cetrelimab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9766
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- 18926165828
- Country
- CHINA
- ProdList
- 198
- Advantage
- 58